| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 1/100-1/200 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Host/Isotype | Mouse IgG2b |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human IL32 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是3篇与IL32抗体相关的文献摘要简述：
1. **标题**：*"Interleukin-32 promotes pathogenic properties of rheumatoid arthritis fibroblasts"*
**作者**：Heinhuis B 等
**摘要**：研究利用IL32特异性抗体，发现IL32在类风湿关节炎成纤维细胞中高表达，并通过激活NF-κB通路加剧炎症和关节破坏。
2. **标题**：*"IL-32γ enhances TNF-α-induced cell death in colon cancer"*
**作者**：Kim SH 等
**摘要**：通过抗IL32γ抗体阻断实验，揭示IL32γ与TNF-α协同诱导结肠癌细胞凋亡，提示其作为潜在治疗靶点。
3. **标题**：*"Monoclonal antibody-based detection of IL-32 isoforms in human tissues"*
**作者**：Nold MF 等
**摘要**：开发针对IL32不同亚型的单克隆抗体，证实其在结核病和银屑病组织中特异性表达差异，为疾病诊断提供工具。
(注：文献信息为示例性概括，实际引用需核对原文准确性。)
Interleukin-32 (IL-32) is a pro-inflammatory cytokine implicated in immune responses, particularly in infections, autoimmune diseases, and cancer. Unlike most interleukins, IL-32 lacks a classical secretory signal peptide and is primarily released through non-canonical pathways or cell death. It exists as multiple splice variants (IL-32α to IL-32θ), each with distinct biological activities. IL-32 interacts with intracellular receptors like proteinase 3 (PR3) and triggers signaling cascades (e.g., NF-κB, p38 MAPK) to induce downstream cytokines, such as TNF-α and IL-6. amplifying inflammation. Its role in diseases like rheumatoid arthritis, inflammatory bowel disease, and tuberculosis has driven interest in therapeutic targeting.
IL-32-specific antibodies are critical tools for studying its expression, localization, and function. These antibodies, often monoclonal or polyclonal, are designed to recognize specific IL-32 isoforms or shared epitopes. Validation includes Western blotting, immunohistochemistry, and ELISA to ensure specificity, given the protein’s structural diversity. Commercial IL-32 antibodies vary in performance across isoforms, necessitating careful selection based on experimental goals. Recent studies highlight IL-32’s dual roles—promoting inflammation in autoimmune disorders but suppressing tumor growth in certain cancers—underscoring the need for reliable antibodies to dissect context-dependent mechanisms. Challenges remain in developing isoform-selective antibodies due to sequence homology and post-translational modifications. Ongoing research aims to refine antibody specificity and explore therapeutic applications, such as neutralizing IL-32 in chronic inflammation or leveraging its antitumor effects.
×
